Novartis has announced the formation of Borealis Biosciences, an independent, discovery-stage biotechnology company focused on developing next-generation xRNA-based medicines for kidney diseases. The new company is a result of a partnership between Novartis and Versant Ventures, and is based in Vancouver, Canada.   Borealis emerged from the successful acquisition of Chinook Therapeutics by Novartis in 2023. Recognizing the significant scientific potential of Chinook’s early research tale...